Le Lézard
Classified in: Science and technology
Subjects: Photo/Multimedia, Product/Service

Arthur D. Little Publishes Human After All ? Latest Edition of PRISM Magazine


Arthur D. Little (ADL) has published Human After All ? the latest edition of its strategy and innovation magazine PRISM. As we enter the era of AI, the first edition of 2024 highlights the importance of taking a human-centric approach to business management.

The magazine features seven key articles:

Ignacio García Alves, Global Chairman and Chief Executive Officer of Arthur D. Little, comments: "Technological innovation, especially AI, is often in the headlines as a threat to humans, but it is the combination of AI and humans together that will be transformative for business and society. This issue of PRISM explains why organizations need to take a fresh look at the human dimension if they are to thrive moving forward in an AI future."

This latest edition of PRISM can be viewed here: https://tinyurl.com/5n7ca5hs

For further information, please visit www.adlittle.com


These press releases may also interest you

at 19:04
X Financial (the "Company"), a leading online personal finance company in China, today announced it filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission ("SEC") on April 29,...

at 19:00
CEAT Specialty hosted the Achievers Meet 2024, aimed to fortify bonds with Australian channel partners, featuring an immersive IPL match experience at Delhi's Arun Jaitley Stadium. Amidst the charged atmosphere on April 27th, attendees witnessed the...

at 18:55
Voxtur Analytics Corp. ("Voxtur" or the "Company"), a North American technology company creating a more transparent and accessible real estate lending ecosystem, today announced its financial results for the three months and year ended December 31,...

at 18:45
Pfizer Inc. and Genmab A/S today announced the U.S. Food and Drug Administration (FDA) approves the supplemental Biologics License Application (sBLA) granting full approval for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with...

at 18:45
Genmab A/S and Pfizer Inc. announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) for the treatment of patients with recurrent or...

at 18:45
Pond Technologies Holdings Inc. (the "Corporation" or "Pond")  announces the filing of the audited consolidated financial statements of the Corporation for the twelve months ended December 31, 2023 and the related management's discussion and analysis...



News published on and distributed by: